Search Results 1-20 of 358

  • Sixteen cases of HER2-positive Breast Cancer treated with Neoadjuvant Chemotherapy with Pertuzumab.

    ABE Hajime , TERAMOTO Atsuko , TAKEI Yumiko , YONEDA Kohri , TANAKA Yoshihito

    … Pertuzumab is a molecular-targeted drug that binds to the extracellular domain of human epidermal growth factor receptor 2 (HER2) and inhibits dimer formation. …

    滋賀医科大学雑誌 33(1), 17-22, 2020-05-01

    IR  DOI 

  • Discovery of Molecular Glues to Induce Selective Protein Degradation, Leading to Development of New Modalities with Targeted Protein Knockdown Function  [in Japanese]

    上原 泰介 , 大和 隆志

    有機合成化学協会誌 = Journal of synthetic organic chemistry, Japan 78(5), 414-420, 2020-05

  • Genetic Alterations Trigger in Cancers  [in Japanese]

    角南 久仁子

    医療 = Japanese journal of National Medical Services : 国立医療学会誌 74(1), 33-37, 2020-01

    Ichushi Web 

  • Multiple myeloma: a focus on drugs under development  [in Japanese]

    SUNAMI Kazutaka

    <p>多発性骨髄腫(multiple myeloma, MM)は21世紀に入り,プロテアソーム阻害薬,免疫調節薬および抗体医薬の登場にて,飛躍的に予後は改善してきている。しかし,このような有効性の高いMM治療薬の開発にもかかわらず,薬剤耐性を来し,標準療法に抵抗性を示し,未だ治癒が見込めないのが現状である。ところがここ1~2年で新規分子標的薬(venetoclax,selinexor) …

    Rinsho Ketsueki 61(5), 520-527, 2020

    J-STAGE 

  • Next-generation Antibody-drug Conjugates (ADCs): Exploring New Frontiers with Chemical Approaches  [in Japanese]

    Anami Yasuaki , Tsuchikama Kyoji

    … <p>Antibody-drug conjugates (ADCs) are an emerging drug format of chemotherapy agents with durable therapeutic efficacy and high target specificity. … Currently, seven ADCs are approved by the U.S. Food and Drug Administration (FDA), and more than 100 ADCs are in clinical trials. …

    Journal of Synthetic Organic Chemistry, Japan 78(5), 503-515, 2020

    J-STAGE 

  • Discovery of Molecular Glues to Induce Selective Protein Degradation, Leading to Development of New Modalities with Targeted Protein Knockdown Function  [in Japanese]

    Uehara Taisuke , Owa Takashi

    … <p>The molecular glue that connects two different proteins is a unique but not an entirely new chemical entity. … One of the notable research achievements with this molecular class is sequential identification of molecular mechanisms of two immunosuppressive natural products FK506 and rapamycin. … Importantly, the molecular glue story has recently been extended to synthetic small molecule space as well. …

    Journal of Synthetic Organic Chemistry, Japan 78(5), 414-420, 2020

    J-STAGE 

  • Genetic analysis and targeted therapy for acute myeloid leukemia  [in Japanese]

    YAMAGUCHI Hiroki

    <p>急性骨髄性白血病(AML)は,近年の遺伝子変異解析技術の進歩によってその発症や再発に関与をする多くの遺伝子変異が発見された。こうしたゲノム解析の結果は予後因子や微少残存病変マーカーとして臨床応用をされるだけでなく新規の分子標的薬創薬に貢献をしている。実際に欧米からは第一世代FLT3阻害薬,IDH1/2阻害薬,BCL2阻害薬など多くの新規薬剤が登場をし,本邦からも第二世代FLT3阻 …

    Rinsho Ketsueki 61(4), 350-357, 2020

    J-STAGE 

  • LPA-induced increase in triple-negative breast cancer stem cells via IL-8 production.  [in Japanese]

    Hirata Naoya , Yamada Shigeru , Kanda Yasunari

    … <p>Triple-negative breast cancer (TNBC) is a highly aggressive cancer with fewer effective targeted therapy. … Since growing evidence suggests that TNBC is originated from breast cancer stem cells (BCSCs), it is required to elucidate the molecular mechanism of BCSC proliferation for new drug development. …

    Proceedings for Annual Meeting of The Japanese Pharmacological Society 93(0), 3-P-372, 2020

    J-STAGE 

  • Rapid measurement of plasma concentration of a molecular-targeted agent, pazopanib, with diamond sensor.  [in Japanese]

    Takuro Saiki , Saijo Yasuo , Hibino Hiroshi , Ogata Genki , Kato Rito , Razvina Olga , Sawamura Seishiro , Matsumoto Yoshifumi , Hanawa Ai , Asai Kai , Einaga Yasuaki

    … <p>Molecular-targeted anticancer drugs elicit less toxicity than conventional reagents. … administration of the drug to all the patients regardless of their body size and complications; … Although frequent measurement of the drug level at a clinical site is a solution, currently available methods such as mass spectrometry are time and cost consuming. …

    Proceedings for Annual Meeting of The Japanese Pharmacological Society 93(0), 1-YIA-18, 2020

    J-STAGE 

  • The activation mechanism and drug discovery of G protein-coupled receptor  [in Japanese]

    Yuan Shunguang

    … In spite of this medical importance and the recent progress in elucidating the 3D structures of various GPCRs, central questions how these receptors recognize extracellular chemical signals and transfer them across the cellular membrane to finally evoke an intracellular response are largely unresolved at a molecular level, mainly because the different steps during signal transmission are not directly accessible by experiments. …

    Proceedings for Annual Meeting of The Japanese Pharmacological Society 93(0), 1-SL03, 2020

    J-STAGE 

  • Investigator-initiated clinical trial of an anti-cancer drug targeted on LAT1  [in Japanese]

    Hikita Hayato , Harada Hideaki , Sigekawa Minoru , Kato Yukio , Nagamori Shushi , Kanai Yoshikatsu , Takehara Tetsuo

    <p>LAT1 (L-type amino acid transporter 1: SLC7A5) is an amino acid transporter. While normal cells intake amino acids by LAT2, tumor cells intake amino acids by LAT1. In pancreatic cancer, LAT1 …

    Proceedings for Annual Meeting of The Japanese Pharmacological Society 93(0), 1-CS-3, 2020

    J-STAGE 

  • Clinicopathological Study of the Immunohistological Expression of mTOR and Phosphorylated mTOR in Renal Cell Carcinoma

    MIZUKAMI SAINOSUKE , NAGATA MASAYOSHI , TAKAHASHI HIROYUKI , HORIE SHIGEO

    … Treatment of metastatic RCC often relies on molecular targeted drug therapy, which has become the mainstream approach. … Recently, the mTOR inhibitors are one typical molecular targeting drug for metastatic RCC. …

    Juntendo Medical Journal, 2020

    J-STAGE 

  • Development of Cancer-targeted Theranostics Probes Based on the Physicochemical Properties of Water-soluble Macromolecules  [in Japanese]

    Sano Kohei

    … <p>Water-soluble macromolecules, such as polymers and monoclonal antibodies, have some advantages, including high water solubility, high biocompatibility, a wide range of molecular weights, and amenability to easy modification through the terminal attachment of functional groups. …

    YAKUGAKU ZASSHI 140(2), 117-122, 2020

    J-STAGE 

  • YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers

    Takeda Tatsuaki , Yamamoto Hiromasa , Suzawa Ken , Tomida Shuta , Miyauchi Shunsaku , Araki Kota , Nakata Kentaro , Miura Akihiro , Namba Kei , Shien Kazuhiko , Soh Junichi , Shien Tadahiko , Kitamura Yoshihisa , Sendo Toshiaki , Toyooka Shinichi

    Molecular-targeted therapies directed against human epidermal growth factor receptor 2 (HER2) are evolving for various cancers. … Neratinib is an irreversible pan-HER tyrosine kinase inhibitor and has been approved by the FDA as an effective drug for HER2-positive breast cancer. …

    Cancer Science 111(3), 849-856, 2019-12-19

    IR 

  • Induced pluripotent stem cell–based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients

    Imamura Keiko , Izumi Yuishin , Banno Haruhiko , Uozumi Ryuji , Morita Satoshi , Egawa Naohiro , Ayaki Takashi , Nagai Makiko , Nishiyama Kazutoshi , Watanabe Yasuhiro , Hanajima Ritsuko , Oki Ryosuke , Fujita Koji , Takahashi Naoto , Ikeda Takafumi , Shimizu Akira , Morinaga Akiko , Hirohashi Tomoko , Fujii Yosuke , Takahashi Ryosuke , Inoue Haruhisa

    … Induced pluripotent stem cell (iPSC)-based drug repurposing identified an Src/c-Abl inhibitor, bosutinib, as a candidate molecular targeted therapy for ALS. …

    BMJ Open 9(12), 2019-12-02

    IR 

  • Molecular targeted therapy for medullary thyroid cancer  [in Japanese]

    田村 真吾 , 内野 慶太

    腫瘍内科 = Clinical oncology 24(4), 352-355, 2019-10

    Ichushi Web 

  • Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer

    Miao Wenyu , Sakai Katsuya , Sato Hiroki , Imamura Ryu , Jangphattananont Nawaphat , Takagi Junichi , Nishita Michiru , Minami Yasuhiro , Matsumoto Kunio

    … Aberrant activation of the MET/hepatocyte growth factor (HGF) receptor participates in the malignant behavior of cancer cells, such as invasion-metastasis and resistance to molecular targeted drugs. … The V370D mutation abrogated HGF-dependent drug resistance of lung cancer cells to epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI). …

    Cancer Science 110(10), 3340-3349, 2019-10

    IR 

  • Challenge to Cure Lung Cancer by Drug : Past Present and Future  [in Japanese]

    中西 洋一

    … Development of drug therapy for lung cancer originates in cytotoxic drugs. … The paradigm shifted in 21st century due to a development of molecular targeted therapy followed by discovery of driver gene mutation. … Today, selection of appropriate drug for patient with non-small cell lung cancer (NSCLC) is based on biomarker test including driver gene mutation, resulting in enhancement of therapeutic effects and avoidance of ineffective drugs. …

    福岡医学雑誌 = Fukuoka acta medica 110(3), 146-150, 2019-09-25

    IR  Ichushi Web 

  • Chemopreventive and anticancer activity of flavonoids and its possibility for clinical use by combining with conventional chemotherapeutic agents

    菊地 秀与 , 袁 博 , Hu Xiaomei , 岡﨑 真理

    … Conventional cancer treatment modalities include antitumor drugs, surgical resection, locally targeted therapies such as radiation therapy. … Along with improved understanding of the molecular pathogenesis of various cancers, generation and the use of smart targeted anti-cancer drugs have been challenged. … The need for novel therapeutic strategies remains paramount given the sustained development of drug resistance, tumor recurrence, and metastasis. …

    American Journal of Cancer Research 9(8), 1517-1535, 2019-08

    IR 

  • Pleural mesothelioma  [in Japanese]

    大塚 憲司 , 安宅 信二

    呼吸器内科 = Respiratory medicine 36(1), 27-33, 2019-07

    Ichushi Web 

Page Top